DPP-IV inhibitors are primarily used in the management of type 2 diabetes. They work by inhibiting the enzyme dipeptidyl peptidase-4, which increases the levels of incretin hormones. These hormones help regulate blood sugar by stimulating insulin release and reducing glucagon production. As a result, DPP-IV inhibitors help lower blood glucose levels, especially after meals. They are often prescribed as part of a combination therapy with other antidiabetic medications, such as metformin, to achieve better glycemic control. Additionally, they are well-tolerated and have a low risk of causing hypoglycemia, making them a suitable option for many patients. These inhibitors are also being studied for potential benefits in other conditions, such as cardiovascular diseases and inflammatory disorders, due to their role in modulating various biological pathways.